First-in-Class IBRANCE + fulvestrant

Palbociclib (IBRANCE) + fulvestrant for postmenopausal women or premenopausal women receiving ovarian suppression with an LHRH agonist with HR+/HER2- MBC that has progressed on or after prior adjuvant or metastatic endocrine therapy1*
*Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.1
If there is disease progression while on CDK4/6 inhibitor therapy, there are no data to support an additional line of therapy with another CDK4/6-containing regimen.1
LHRH=luteinizing hormone-releasing hormone; MBC=metastatic breast cancer; NCCN®=National Comprehensive Cancer Network®.
REFERENCE
1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed April 13, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.